Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Vilon

KE, L-Lys-L-Glu, lysylglutamic acid

Quick Stats
Studies 40
Trials 100
Recruiting NA INTERVENTIONAL NCT05534607

Natives Engaged in Alzheimers Research - 'Ike Kupuna

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

This study will conduct a group randomized trial to test the effects of a hula-based intervention in improving vascular risk factors for ADRD and cognitive complaints and function over 12 months.

Detailed Description

This study will conduct a pragmatic group-randomized trial (GRT) with NHPIs aged 50-75 years with at least 1 of 4 modifiable vascular risk factors for ADRD (hypertension, hyperglycemia, obesity, or dyslipidemia) and either SCI or MCI using a wait-list control design to test the effects of the hula-based intervention. The primary outcomes will be vascular risk factors for ADRD and subjective cognitive complaints. Secondary outcomes will include measures of cognitive performance, physical function, and mental health.

Interventions

Name: Ola Mau i ka Hula
Type: BEHAVIORAL
Description: The first 3 months of the hula-based intervention program was designed and standardized as a culturally-based physical activity (PA) that includes 15 minutes of ADRD education and intervention orientation with 12 weeks of hula lessons. These hula lessons consist of two 60-minute classes per week over 12 weeks. Each hula lesson will consist of 8 participants, providing them with the opportunity to engage-in this social support network. For the remaining 5 months of the Ola Mau i ka Hula Program, hula lessons led by the kumu hula will be reduced to once a month for 60 min. In addition, the intervention group will meet with a community-peer educator weekly over this 5-month period. Each meeting will be 90 minutes in length with 60 minutes of hula practice following the same format as previous classes, and 30 minutes will cover the PILI Lifestyle Plan curriculum and cultural-based cognitive exercises, alternating weekly.

Primary Outcomes

Measure: Change in participants' systolic blood pressure at each time frame from baseline
TimeFrame: 3 months, 8 months, 12 months
Description: Vascular risk factor assessed using Omron©HEM-907XL
Measure: Change in participants' Hemoglobin A1c at each time frame from baseline
TimeFrame: 12 months
Description: Vascular risk factor assessed using Alere Cholestech LDX® System
Measure: Change in participants' total cholesterol at each time frame from baseline
TimeFrame: 3 months, 8 months, 12 months
Description: Vascular risk factor assessed using Alere Cholestech LDX® System
Measure: Change in participants' body mass index at each time frame from baseline
TimeFrame: 3 months, 8 months, 12 months
Description: Vascular risk factor assessed using Tanita BWB800AS scale
Measure: Change in participants' Cognitive Change Index score at each time frame from baseline
TimeFrame: 3 months, 8 months, 12 months
Description: Cognitive function assessed using Cognitive Change Index assessment
Measure: Change in participants' Number Symbol Coding Test score at each time frame from baseline
TimeFrame: 3 months, 8 months, 12 months
Description: Cognitive function assessed using Number Symbol Coding Test
Measure: Change in participants' overall Cognivue score at each time frame from baseline
TimeFrame: 3 months, 8 months, 12 months
Description: Cognitive function assessed using Cognivue device
Measure: Change in participants' overall Quick Dementia Rating System score at each time frame from baseline
TimeFrame: 3 months, 8 months, 12 months
Description: Cognitive function assessed using Quick Dementia Rating System assessment

Trial Information

NCT ID

NCT05534607

Status

Recruiting

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

University of Hawaii

Last Updated

December 15, 2025